Chiesi Takes Aim At Next-Generation Eosinophilic Asthma Therapy
Chiesi may be coming late to the development of eosinophilic asthma therapies, but there are certain advantages associated with acquisition target Atopix Therapeutics’ potential products that could strengthen the specialty pharma's already significant presence in the asthma market.
You may also be interested in...
Novartis is advancing studies with its experimental asthma therapy fevipiprant in India, amid significant expectations around its possible impact on market dynamics including aspects such as the potentially shared patient pool with certain biologics.
Five of the nine products that could this week be recommended for EU approval have orphan designation. The final meeting this year of the European Medicines Agency’s key scientific committee, the CHMP, is under way in London.
In another vote of confidence in one of its newer respiratory assets, AstraZeneca is extending to Asia its already broad rights to benralizumab, adding to a deal it already has with Kyowa Hakko Kirin for Japan.